Simultaneous changes in expression levels of BAALC and miR-326: a novel prognostic biomarker for childhood ALL
- 1 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 50 (6), 671-678
- https://doi.org/10.1093/jjco/hyaa025
Abstract
Objective: Multidrug resistance and consequent relapse are two major obstacles for treating children with acute lymphoblastic leukemia,the most frequent childhood malignancy. MicroRNAs have potential regulatory roles in response to chemotherapy. The goal of this study was to determine the microRNA that may have effects on the expression level of brain and acute lymphoblastic leukemia (BAALC) and to investigate the in vitro and ex vivo association between their expression levels. Methods: In silico tools were utilized to determine a putative miRNA targeting BALLC. Quantitative real-time polymerase chain reaction was used to investigate expression levels of BAALC and its predicted microRNA, miR-326, in bone marrow samples of 30 children with acute lymphoblastic leukemia and 13 controls, in addition to the resistant and parental CCRF-CEM cell lines. To assess the status of response to therapy, minimal residual disease was measured using single-strand conformation polymorphism. Results: MiR-326 was selected due to the strong possibility of its interaction with BAALC according to the obtained in silico results. Statistical analysis showed a significant downregulation of miR-326 and overexpression of BALLC in drug-resistant acute lymphoblastic leukemia cell line and patients compared with the parental cell line and drug-sensitive patients, respectively (P = 0.015, 0.005, 0.0484 and 0.0005, respectively). The expression profiles of miR-326 and BAALC were inversely correlated (P = 0.028). Conclusions: The results introduced the inversely combined expression levels of miR-326 and BAALC as a novel, independent prognostic biomarker for pediatric acute lymphoblastic leukemia (P= 0.007). Moreover, bioinformatics data showed a possible regulatory role for miR-326 on BAALC mRNA, which may possibly contribute to the development of drug resistance in patients with childhood acute lymphoblastic leukemia.Keywords
This publication has 32 references indexed in Scilit:
- BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemiaBlood Cancer Journal, 2014
- MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapyJournal of Biomedical Science, 2013
- Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practiceCritical Reviews in Oncology/Hematology, 2012
- miRWalk – Database: Prediction of possible miRNA binding sites by “walking” the genes of three genomesJournal of Biomedical Informatics, 2011
- Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical modelsAnnals of Hematology, 2010
- High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemiaBlood, 2010
- High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyBlood, 2008
- MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed PairingMolecular Cell, 2007
- Advanced Maternal Age and Adverse Perinatal OutcomeObstetrics & Gynecology, 2004
- BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemiaProceedings of the National Academy of Sciences of the United States of America, 2001